NEW YORK (GenomeWeb News) – Beckman Coulter plans to acquire diagnostics company Biosite for about $1.55 billion in cash, the companies said this weekend.
 
Under the deal, Beckman would pay $85 a share for all of Biosite’s common stock, which closed at $55.38 on the Nasdaq Friday.
 
Beckman, which expects the acquisition will increase its footprint in the immunoassay market, said the deal came from a four-year relationship between the companies based on a test that for coronary syndromes. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.